Clinical trials: Hyperuricemia or Gout
Gout
Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010
The purpose of this study is to determine the long-term safety of febuxostat, once daily (QD), compared to allopurinol in reducing serum urate levels in subjects with gout.
- Trial name
- EXCEL (NCT00175019)
- Testing
- Febuxostat, Allopurinol
- Volunteers
- 1,086 people
- Sponsor
- Takeda
Gout Patients
Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients
The study is designed to evaluate the PK/PD, safety and tolerability of AR882 alone or in combination with febuxostat or allopurinol when administered to gout patients.
- Trial name
- NCT04155918
- Testing
- Group 1: AR882 Alone and in Combination with Febuxostat (FBX), Group 2: AR882 Alone and in Combination with Allopurinol (ALLO)
- Where
- New Zealand
- Volunteers
- 30 people
- Sponsor
- Arthrosi Therapeutics
Hyperuricemia
Study of FYU-981 in Hyperuricemia With or Without Gout
The purpose of this study is exploratory investigation of safety and efficacy (dose response and optimal dose according to the percent reduction from baseline in serum urate level at the final visit) of FYU-981 administered…
- Trial name
- NCT02344862
- Testing
- FYU-981 High dose, (Oral daily dosing for 8 weeks), FYU-981 Middle dose, (Oral daily dosing for 8 weeks), FYU-981 Low dose, (Oral daily dosing for 8 weeks)
- Where
- Japan
- Volunteers
- 80 people
- Sponsor
- Fuji Yakuhin Co., Ltd.